...and hepatitis B virus (HBV). TARGET/MARKER/PATHWAY: Caspase-1 (CASP1) LICENSING STATUS: Patent application filed; licensed to iVeena Pharmaceuticals Inc....

...it to treat wet AMD. The approach for treating dry AMD has been licensed to iVeena Pharmaceuticals Inc....
...vitreous and aqueous samples from living patients with varying stages of AMD," he said. Meanwhile, iVeena Pharmaceuticals...
...Medicine of Case Western Reserve University , Cleveland, Ohio Harvard Medical School , Boston, Mass. iVeena Pharmaceuticals Inc....

...in the mice, a peptide-based MYD88 inhibitor prevented Alu RNA-induced retinal damage. Next steps at iVeena Pharmaceuticals Inc....